Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
clofarabine | NDA authorized generic | 2023-12-07 |
clolar | New Drug Application | 2023-11-15 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
lymphoid leukemia | — | D007945 | C91 |
Code | Description |
---|---|
J9027 | Injection, clofarabine, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myeloid leukemia acute | D015470 | — | C92.0 | 22 | 48 | 5 | — | 2 | 67 |
Myelodysplastic syndromes | D009190 | — | D46 | 21 | 32 | 2 | — | — | 46 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 16 | 28 | 3 | — | 1 | 42 |
Leukemia | D007938 | — | C95 | 24 | 28 | 3 | — | 1 | 42 |
Myeloid leukemia | D007951 | — | C92 | 1 | 1 | 1 | — | — | 3 |
Bone marrow transplantation | D016026 | — | — | 1 | — | 1 | — | — | 2 |
Megakaryoblastic leukemia acute | D007947 | — | C94.2 | 1 | — | 1 | — | — | 2 |
Monocytic leukemia acute | D007948 | — | — | 1 | — | 1 | — | — | 2 |
Myelomonocytic leukemia acute | D015479 | — | C92.5 | 1 | — | 1 | — | — | 2 |
Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 1 | — | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-hodgkin lymphoma | D008228 | — | C85.9 | 7 | 12 | — | — | — | 15 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 3 | 9 | — | — | — | 11 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 4 | 7 | — | — | — | 10 |
Hodgkin disease | D006689 | — | C81 | 6 | 8 | — | — | — | 10 |
Neoplasms | D009369 | — | C80 | 7 | 3 | — | — | 1 | 9 |
Lymphoma | D008223 | — | C85.9 | 7 | 7 | — | — | — | 9 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 5 | 5 | — | — | — | 8 |
Multiple myeloma | D009101 | — | C90.0 | 3 | 6 | — | — | — | 7 |
Hematologic neoplasms | D019337 | — | — | 4 | 1 | — | — | 1 | 5 |
Burkitt lymphoma | D002051 | — | C83.7 | 2 | 4 | — | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myeloproliferative disorders | D009196 | — | D47.1 | 2 | — | — | — | — | 2 |
Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 1 | — | — | — | — | 1 |
Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
Neutropenia | D009503 | — | D70 | 1 | — | — | — | — | 1 |
Bone marrow diseases | D001855 | — | — | 1 | — | — | — | — | 1 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | — | — | — | 1 |
Crohn disease | D003424 | EFO_0000384 | K50 | 1 | — | — | — | — | 1 |
Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | 1 | — | — | — | — | 1 |
Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | 1 | — | — | — | — | 1 |
Takayasu arteritis | D013625 | EFO_1001857 | M31.4 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Peroxisomal disorders | D018901 | Orphanet_44 | E71.5 | — | — | — | — | 1 | 1 |
Lysosomal storage diseases | D016464 | — | — | — | — | — | — | 1 | 1 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | — | 1 | 1 |
Thalassemia | D013789 | EFO_1001996 | D56 | — | — | — | — | 1 | 1 |
Fanconi anemia | D005199 | Orphanet_84 | D61.09 | — | — | — | — | 1 | 1 |
Melanoma | D008545 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Clofarabine |
INN | clofarabine |
Description | Clofarabine is a purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia. It has a role as an antineoplastic agent and an antimetabolite. It is an organofluorine compound and a member of adenosines. |
Classification | Small molecule |
Drug class | antineoplastics (arabinofuranosyl derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F |
PDB | — |
CAS-ID | 123318-82-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1750 |
ChEBI ID | 681569 |
PubChem CID | 119182 |
DrugBank | DB00631 |
UNII ID | 762RDY0Y2H (ChemIDplus, GSRS) |